Acerus Announces Amendments to Loan Facility
March 31, 2022 07:30 ET
|
Acerus Pharmaceuticals Corporation
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with...
Acerus Reports Fourth Quarter and Full Year 2021 Financial Results
March 15, 2022 07:30 ET
|
Acerus Pharmaceuticals Corporation
TORONTO, March 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and...
Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call
March 10, 2022 07:30 ET
|
Acerus Pharmaceuticals Corporation
TORONTO, March 10, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its fourth quarter and full year 2021 financial and operating results on Tuesday,...
Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva™
March 07, 2022 17:30 ET
|
Acerus Pharmaceuticals Corporation
TORONTO, March 07, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the closing of its previously-announced acquisition...
Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™
February 28, 2022 07:30 ET
|
Acerus Pharmaceuticals Corporation
Creating a Leading Urology & Men’s Health Pharmaceutical Company Acerus to have access to two significant and growing addressable markets that represent more than 40 million people in the United...
Acerus Announces Amendment to Loan Facilities
February 18, 2022 07:30 ET
|
Acerus Pharmaceuticals Corporation
TORONTO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with...
Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto Rico
January 10, 2022 07:30 ET
|
Acerus Pharmaceuticals Corporation
Verity Pharmaceuticals will begin promoting NATESTO to health care professionals throughout Puerto Rico in Q1, 2022. This agreement represents a new partnership and the continued expansion of NATESTO...
Acerus Announces Amendments to Loan Facilities
December 13, 2021 07:30 ET
|
Acerus Pharmaceuticals Corporation
TORONTO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with...
Acerus Reports Fiscal Third Quarter Financial Results
November 09, 2021 07:30 ET
|
Acerus Pharmaceuticals Corporation
TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and nine-month...
Acerus to Report Q3-2021 Financial Results and Host Investor Call
November 02, 2021 07:30 ET
|
Acerus Pharmaceuticals Corporation
TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its third quarter 2021 financial and operating results on Tuesday, November 9, 2021...